{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-004824","form_type":"8-K","ticker":"INGN","cik":"0001294133","company_name":"Inogen Inc","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.234322+00:00","generated_at":"2026-05-28T02:55:23.518927+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Inogen reports prelim Q4 rev $79M-$80M (+4-5%); FY24 rev $334.5M-$335.5M (+6%), beats guidance","bullets":["Q4 2024 preliminary revenue of $79M-$80M, up 4-5% YoY.","Full-year 2024 preliminary revenue of $334.5M-$335.5M, up 6% YoY, exceeding prior guidance of $329M-$331M.","Driven by strong double-digit B2B revenue growth; DTC revenue stabilization ongoing.","Launched Rove 4 and received FDA clearance for SIMEOX 200 during Q4.","Official Q4/FY results and conference call scheduled for Feb 25, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-004824","json":"https://secwatch.observer/filing/0000950170-25-004824.json","markdown":"https://secwatch.observer/filing/0000950170-25-004824.md","text":"https://secwatch.observer/filing/0000950170-25-004824.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1294133/000095017025004824/0000950170-25-004824-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1294133/000095017025004824/ingn-20250113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T02:55:23.518927+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}